198 related articles for article (PubMed ID: 12242514)
1. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.
Kasper C; Zahner J; Sayer HG
J Cancer Res Clin Oncol; 2002 Sep; 128(9):497-502. PubMed ID: 12242514
[TBL] [Abstract][Full Text] [Related]
2. Measurement of serum cytokine levels in patients with myelodysplastic syndromes.
Verhoef GE; De Schouwer P; Ceuppens JL; Van Damme J; Goossens W; Boogaerts MA
Leukemia; 1992 Dec; 6(12):1268-72. PubMed ID: 1280751
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with rhGM-CSF and rhEpo for two patients with refractory anemia and aplastic anemia.
Takahashi M; Aoki A; Mito M; Nikkuni K; Ohtsuka T; Saitoh H; Moriyama Y; Shibata A
Hematol Pathol; 1993; 7(3):153-8. PubMed ID: 8244908
[TBL] [Abstract][Full Text] [Related]
4. Treatment of myelodysplastic syndromes with hematopoietic growth factors.
Ganser A; Hoelzer D
Hematol Oncol Clin North Am; 1992 Jun; 6(3):633-53. PubMed ID: 1377194
[TBL] [Abstract][Full Text] [Related]
5. Effects of prolonged treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor.
Greenberg P; Negrin R; Nagler A; Vincent M; Donlon T
Int J Cell Cloning; 1990 Jan; 8 Suppl 1():293-300; discussion 300-2. PubMed ID: 1691248
[TBL] [Abstract][Full Text] [Related]
6. Clinical use of recombinant human hematopoietic growth factors (GM-CSF, IL-3, EPO) in patients with myelodysplastic syndrome.
Herrmann F; Mertelsmann R; Lindemann A; Ottmann OG; Seipelt G; Oster W; Hoelzer D; Ganser A
Biotechnol Ther; 1991; 2(3-4):299-311. PubMed ID: 1845132
[TBL] [Abstract][Full Text] [Related]
7. [Combined GM-CSF and erythropoietin therapy in myelodysplastic syndrome].
Egli F; Hofer S; Greminger P; Rhyner K
Schweiz Med Wochenschr; 1989 Dec; 119(49):1777-80. PubMed ID: 2694367
[TBL] [Abstract][Full Text] [Related]
8. [Hematopoietic growth factors in primary and therapy-related bone marrow insufficiency].
Hansen B; Hippe E; Jacobsen GK; Johnsen HE
Ugeskr Laeger; 1992 Jun; 154(24):1697-702. PubMed ID: 1378668
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. EORTC Leukemia Cooperative Group.
Gerhartz HH; Marcus R; Delmer A; Zwierzina H; Suciu S; Dardenne M; Solbu G; de Witte T; Jacobs A; Visani G
Leukemia; 1994 Jan; 8(1):16-23. PubMed ID: 8289481
[TBL] [Abstract][Full Text] [Related]
10. Current use of recombinant human erythropoietin (r-huEPO) in the management of symptomatic anaemia in patients with myelodysplastic syndromes (MDS).
Marques da Costa R
Sangre (Barc); 1994 Apr; 39(2):105-10. PubMed ID: 8059287
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin may improve anemia in selected patients with myelodysplastic syndromes.
Hansen PB; Johnsen HE; Hippe E; Hellström-Lindberg E; Ralfkiaer E
Am J Hematol; 1993 Dec; 44(4):229-36. PubMed ID: 8237992
[TBL] [Abstract][Full Text] [Related]
12. Hemotoxicity by prolonged etoposide administration to mice can be prevented by simultaneous growth factor therapy.
de Haan G; Engel C; Dontje B; Loeffler M; Nijhof W
Cancer Res; 1995 Jan; 55(2):324-9. PubMed ID: 7529132
[TBL] [Abstract][Full Text] [Related]
13. The use of haemopoietic growth factors in the treatment of myelodysplastic syndromes.
Greenberg PL; Negrin R; Nagler A
Cancer Surv; 1990; 9(1):199-212. PubMed ID: 2276114
[TBL] [Abstract][Full Text] [Related]
14. Sequential administration of recombinant human granulocyte-macrophage colony-stimulating factor and human erythropoietin for treatment of myelodysplastic syndromes.
Runde V; Aul C; Ebert A; Grabenhorst U; Schneider W
Eur J Haematol; 1995 Jan; 54(1):39-45. PubMed ID: 7859874
[TBL] [Abstract][Full Text] [Related]
15. Clinical applications of recombinant human colony-stimulating factors.
Klingemann HG
CMAJ; 1989 Jan; 140(2):137-42. PubMed ID: 2642725
[TBL] [Abstract][Full Text] [Related]
16. Treatment of myelodysplastic syndromes with cytokines and cytotoxic drugs.
Ganser A; Seipelt G; Eder M; Geissler G; Ottmann OG; Hess U; Hoelzer D
Semin Oncol; 1992 Apr; 19(2 Suppl 4):95-101. PubMed ID: 1372766
[TBL] [Abstract][Full Text] [Related]
17. Restoration of impaired cytokine secretion from monocytes of patients with myelodysplastic syndromes after in vivo treatment with GM-CSF or IL-3.
Maurer AB; Ganser A; Buhl R; Seipelt G; Ottmann OG; Mentzel U; Geissler RG; Hoelzer D
Leukemia; 1993 Nov; 7(11):1728-33. PubMed ID: 8231242
[TBL] [Abstract][Full Text] [Related]
18. Impact of marrow cytogenetics and morphology on in vitro hematopoiesis in the myelodysplastic syndromes: comparison between recombinant human granulocyte colony-stimulating factor (CSF) and granulocyte-monocyte CSF.
Nagler A; Binet C; Mackichan ML; Negrin R; Bangs C; Donlon T; Greenberg P
Blood; 1990 Oct; 76(7):1299-307. PubMed ID: 1698477
[TBL] [Abstract][Full Text] [Related]
19. Treatment with very low-dose GM-CSF in myelodysplastic syndromes with neutropenia. A report on 28 cases.
Rose C; Wattel E; Bastion Y; Berger E; Bauters F; Coiffier B; Fenaux P
Leukemia; 1994 Sep; 8(9):1458-62. PubMed ID: 8090025
[TBL] [Abstract][Full Text] [Related]
20. Is granulocyte-macrophage colony-stimulating factor (GM-CSF) safe in myelodysplastic syndromes?
Mittelman M; Floru S; Pick AI
Haematologia (Budap); 1994; 26(2):111-5. PubMed ID: 7890261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
